R Squared’s Ultragenyx Pharmaceutical RARE Stock Holding History

R Squared’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,460	Closed	-$103K	–	1207
2024 Q4	$103K	Buy	+2,460	New	+$122K	0.1%	248

Other funds holding RARE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

R Squared's RARE Position: Q1 2025 in Review

R Squared sold out of Ultragenyx Pharmaceutical (RARE) in Q1 2025, closing a stake of 2,460 shares — an estimated $103K sold.

R Squared first reported a position in RARE in Q4 2024 and held it in 1 quarter. The position peaked at $103K in Q4 2024. 299 funds tracked by Wall St. Rank hold RARE as of Q1 2025.

R Squared reported no remaining Ultragenyx Pharmaceutical position as of Q1 2025 after selling out during the quarter.
R Squared sold 2,460 Ultragenyx Pharmaceutical shares in Q1 2025, an estimated $103K.
R Squared first reported a position in Ultragenyx Pharmaceutical in Q4 2024 and held it in 1 quarter.
R Squared's Ultragenyx Pharmaceutical position peaked at $103K in Q4 2024.
299 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2025.

Based on R Squared's 13F filing for Q1 2025, filed 9 May 2025.